Metrics as of 10/13/2026, 06:42 PM (Berlin time), refresh in progress.
Protagonist Therapeutics Stock
Protagonist Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Dinesh V. Patel
- Employees
- 141
- Market cap
- $8.9 B
- IPO
- 11/08/2016
Protagonist Therapeutics, Inc. is a biopharmaceutical firm based in the United States that is dedicated to discovering and advancing peptide-based therapies. The company was founded in 2006 and maintains its headquarters in Newark, California. Its research primarily focuses on treatments for hematological and blood…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Protagonist Therapeutics stock: price history
1D
-4.4%
1W
-0.1%
1M
-6.5%
6M
+32.2%
YTD
+58.6%
1Y
+74.9%
2Y
+207.2%
5Y
+659.3%
10Y
+545.3%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~47% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 16/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Protagonist Therapeutics
Analyst assessment of Protagonist Therapeutics
PRICE TARGET LOW
US$165.00
CONSENSUS
US$177.25
MEDIAN
US$176.50
PRICE TARGET HIGH
US$190.00
0
STRONG BUY
26
BUY
0
HOLD
0
SELL
0
STRONG SELL
26
TOTAL · Buy
As of: 01/09/2026
Protagonist Therapeutics stock metrics
P/E
113.69
P/B
10.85
EV/EBITDA
98.93
RETURN ON EQUITY
19.4%
NET MARGIN
76.3%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
81.6%
FLOAT SHARES
52,492,872
AVG. DAILY VOLUME (30D)
756,342
Insider transactions (SEC)
Ali Asif
Ali Asif
Ali Asif
Ali Asif
Ali Asif
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -4.4%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Protagonist Therapeutics stock
What does Protagonist Therapeutics do?
Protagonist Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Dinesh V. Patel, the company employs around 141 people.
The IPO was on 11/08/2016; the stock trades on NASDAQ under the ticker PTGX.
What do analysts say about Protagonist Therapeutics stock?
26 analysts rate the stock, the consensus is Buy (as of 01/09/2026).
The average price target is US$177.25, ranging from US$165.00 to US$190.00, with a median of US$176.50.
This is an external assessment, not a statement by Market Jury.
When does Protagonist Therapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -47% stronger than usual.
Does Protagonist Therapeutics pay a dividend?
No, Protagonist Therapeutics currently does not pay a dividend.
Which stocks are comparable to Protagonist Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Protagonist Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Protagonist Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.